The product did not earn approval for all indications of the reference Herceptin; it has been approved only for the treatment of HER2-positive gastric cancers, and not for the treatment of HER2-positive breast cancer.
Nippon Kayaku, a Japanese-based drug developer, announced yesterday that it has launched Celltrion’s biosimilar trastuzumab (Herceptin) product in Japan. The biosimilar, CT-P6, was developed by Celltrion and will be sold by Nippon Kayaku, which has also marketed Celltrion’s infliximab biosimilar, Remsima, in Japan.
An application for the marketing approval of the trastuzumab biosimilar, CT-P6, was submitted to Japan’s Ministry of Health, Labor, and Welfare in April 2017. The product did not earn approval for all indications of the reference product, however; it has been approved only for the treatment of HER2-positive gastric cancers, and not for the treatment of HER2-positive breast cancer.
Click here to read more about CT-P6.
Neither Celltrion nor Nippon Kayaku indicated whether they had sought approval for all indication of the reference Herceptin, though an April 2017 statement by Nippon Kayaku announcing regulatory submission notes that the monoclonal antibody “plays an important role in the treatment of HER2-positive breast cancer,” and in 2015, the company announced the start of a clinical trial of the molecule in patients with breast cancer.
CT-P6 was approved in the European Union in February 2018, and is now sold under the trade name Herzuma. The product is not yet authorized in the United States, however, as Celltrion received a Complete Response Letter (CRL) for the drug in April 2018 from the FDA.
The CRL came after Celltrion had received the FDA’s Form 483 in 2017, noting 12 observations related to a range of issues, including incomplete records, inappropriately designed equipment, deficient environmental monitoring, and inadequate validation of sterilization processes. Then, in February 2018, Celltrion received a warning letter from the agency related to its manufacturing processes. The drug maker has since resubmitted the product to the FDA for approval.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.